Arcutis Biotherapeutics, Inc.
ARQT
Updated: 24/09/2026, 09:05:28
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
No summaries found.
- Share price
- $26.38
- Market cap
- $3.30B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Todd Franklin Watanabe
- Employees
- 354
- IPO date
- 31/01/2020
- Beta
- 1.503
- Last dividend
- $0.00
- Day range
- $26.07 – $28.02
- 52-week range
- $16.57 – $31.77
- 1-day performance
- -5.04%
- 1-year performance
- 59.20%
- Current drawdown (1Y)
- -16.97%
- CIK
- 0001787306
- CUSIP
- 03969K108
- ISIN
- US03969K1088
- Created
- 07/12/2025, 02:09:20
- Last update
- 24/09/2026, 09:05:28
Track Arcutis Biotherapeutics, Inc. with an AI analyst
See which prediction-market events move ARQT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status
MarketBeat • STOCK • 09/06/2026, 22:02:56
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 19:22:10
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
GlobeNewsWire • STOCK • 03/06/2026, 10:00:00
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 02:41:20
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
Zacks Investment Research • STOCK • 06/05/2026, 20:25:46
Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
GlobeNewsWire • STOCK • 22/04/2026, 10:00:00
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
GlobeNewsWire • STOCK • 15/04/2026, 18:00:00
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know
The Motley Fool • STOCK • 08/04/2026, 09:30:19
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
GlobeNewsWire • STOCK • 31/03/2026, 18:00:00
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
GlobeNewsWire • STOCK • 28/03/2026, 12:00:00
Ally Bridge Group NY LLC Invests $4.40 Million in Arcutis Biotherapeutics, Inc. $ARQT
Defense World • STOCK • 15/03/2026, 04:31:24
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) to Participate in TD Cowen Health Care Conference
Market Data • Market Data • 01/03/2026, 20:00:04